• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Sofosbuvir-velpatasvir may provide sustained virologic response in Hepatitis C cirrhotics: The ASTRAL-4 study

byShayna BejaimalandShaidah Deghan, MSc. MD
November 19, 2015
in Chronic Disease, Infectious Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

 

1. Sofosbuvir-velpatasvir with or without ribavirin resulted in sustained virologic response at 12 weeks across all hepatitis C virus (HCV) genotypes in patients with decompensated cirrhosis.

2. Rates of adverse events were similar across all treatment groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: HCV infection has the potential to become a chronic infection causing cirrhosis and thus decompensated liver failure. Currently one of the main management options is liver transplantation. However recent developments in antivirals have opened the doors to medical management that may lead to complete viral suppression. The NS5B nucleotide inhibitor is currently approved for HCV infection however the new velpatasvir is currently in Phase 3 clinical trials. This open-label randomized controlled trial compared sofosbuvir-velpatasvir with and without ribavirin for 12 weeks or sofosbuvir-velpatasvir for 24 weeks in patients infected with HCV genotypes 1 to 6 and decompensated cirrhosis to assess for efficacy and safety.

All three treatment regimens resulted in sustained virologic responses at 12 weeks across all HCV genotypes; meeting the prespecified primary efficacy end point set by study investigators. There was evidence for improvement in liver function as measured by Child-Pugh-Turcotte (CPT) and Model for End-Stage Liver Disease (MELD) scores. Strengths of the study include being a multicenter and randomized study looking at efficacy of these medications in the sick decompensated cirrhosis patient population. A major limitation of this study is that it was not statistically powered to detect significant differences between efficacy and adverse events across treatment groups. Also it must be cautioned extrapolating these results to very ill patients with severe liver disease as the patient population in this study had moderate hepatic decompensation.

Click to read the study, published today in NEJM

RELATED REPORTS

Accessible hepatitis C care for people who inject drugs provide significantly higher rates of cure compared to conventional care

Demographic trends associated with increased maternal & neonatal Hepatitis C cases over 10 years

Adenovirus encoding hepatitis C virus vaccine is safe but effectiveness is unclear

Relevant Reading: Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial

In-Depth [randomized controlled trial]: This 1:1:1 randomized, open-label controlled trial was conducted at 47 sites across the United States. Patients had HCV infection of any genotype and CPT Class B. Both patients not treated and previously treated were included, however those who received liver transplants were excluded. Patients were randomly assigned to either sofosbuvir-velpatasvir for 12 weeks, sofosbuvir-velpatasvir plus ribavirin for 12 weeks or sofosbuvir-velpatasvir for 24 weeks (current duration for standard of care). The primary end point was sustained virologic response at 12 weeks after end of therapy. Liver function as represented by changes in CPT and MELD scores were also analyzed.

In total 438 patients were screened and underwent randomization. Demographics and baseline characteristics were generally well balanced and had representation of almost all HCV genotypes (missing genotype 5). Seventy-eight percent of patients had genotype 1. The median CPT score was 8, Class B, (range 5-10) and MELD score was 10 (range 6 to 24). Overall rates of sustained virologic response for the sofosbuvir-velpatasvir x 12 weeks, sofosbuvir-velpatasvir plus ribavirin and sofosbuvir-velpatasvir x 24 weeks were 83% (95% CI 74%-90%), 94% (95% CI 87%-98%) and 86% (95% CI 77%-92%) respectively.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: hepatitis C
Previous Post

New data on prevalence and spectrum of germline mutations in pediatric cancer patients

Next Post

The SOME trial: Screening for occult malignancy in unprovoked venous thromboembolism [Classics Series]

RelatedReports

Large spike in drug use-associated infective endocarditis linked with opioid epidemic
Gastroenterology

Accessible hepatitis C care for people who inject drugs provide significantly higher rates of cure compared to conventional care

March 17, 2022
Social networks play key roles in parental vaccination decisions
Chronic Disease

Demographic trends associated with increased maternal & neonatal Hepatitis C cases over 10 years

November 1, 2021
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

Adenovirus encoding hepatitis C virus vaccine is safe but effectiveness is unclear

February 10, 2021
Screening insufficient for newborns exposed to hepatitis C virus
Cardiology

Expanding heart transplant in the era of direct-acting antiviral therapy for hepatitis C

December 28, 2019
Next Post
Adverse pregnancy outcomes associated with thrombophilias [Classics Series]

The SOME trial: Screening for occult malignancy in unprovoked venous thromboembolism [Classics Series]

Adverse pregnancy outcomes associated with thrombophilias [Classics Series]

The Magpie trial: Magnesium lowers eclampsia risk [Classics Series]

Infertility treatments not associated with increased short-term cancer risk

Donor egg cycles more successful than autologous oocytes in cancer survivors

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
  • Operating the day after performing surgery the previous night not associated with adverse patient outcomes
  • Gratitude-focused writing may improve mental wellness during periods of chronic stress
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.